Skip to main content

Advertisement

Springer Nature Link
Log in

Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Glioblastoma multiforme is the most aggressive and lethal tumor of the central nervous system with limited treatment strategies on offer, and as such the identification of effective novel therapeutic agents is paramount. To examine the efficacy of proteasome inhibitors, we tested bortezomib, carfilzomib, nafamostat mesylate, gabexate mesylate and acetylsalicylic acid on glioblastoma cell viability, migration and invasion. Both bortezomib and carfilzomib produced significant reduction of cell viability, while nafamostat mesylate, gabexate mesylate and acetylsalicylic acid did not. Subsequent testing showed that carfilzomib significantly reduced cell viability at nM concentrations. Carfilzomib also reduced cell migration, secretion and activation of MMP2 and also cell invasion of all four glioblastoma cells tested. In summary, carfilzomib represents a novel, yet FDA-approved agent for the treatment of glioblastoma multiforme.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Adamson C, Kanu OO, Mehta AI, Di C, Lin N, Mattox AK, et al. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs. 2009;18(8):1061–83.

    Article  CAS  PubMed  Google Scholar 

  2. Milano MT, Okunieff P, Donatello RS, Mohile NA, Sul J, Walter KA, et al. Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys. 2010;78(4):1147–55.

    Article  CAS  PubMed  Google Scholar 

  3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.

    Article  CAS  PubMed  Google Scholar 

  4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.

    Article  CAS  PubMed  Google Scholar 

  5. Gan HK, Rosenthal MA, Cher L, Dally M, Drummond K, Murphy M, et al. Management of glioblastoma in Victoria, Australia (2006–2008). J Clin Neurosci. 2015;22(9):1462–6.

    Article  PubMed  Google Scholar 

  6. Burkhardt JK, Hofstetter CP, Santillan A, Shin BJ, Foley CP, Ballon DJ, et al. Orthotopic glioblastoma stem-like cell xenograft model in mice to evaluate intra-arterial delivery of bevacizumab: from bedside to bench. J Clin Neurosci. 2012;19(11):1568–72.

    Article  CAS  PubMed  Google Scholar 

  7. Luwor RB, Stylli SS, Kaye AH. The role of Stat3 in glioblastoma multiforme. J Clin Neurosci. 2013;20(7):907–11.

    Article  CAS  PubMed  Google Scholar 

  8. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000;14(4):391–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Engebraaten O, Bjerkvig R, Pedersen PH, Laerum OD. Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumour biopsies in vitro. Int J Cancer. 1993;53(2):209–14.

    Article  CAS  PubMed  Google Scholar 

  10. El-Obeid A, Bongcam-Rudloff E, Sorby M, Ostman A, Nister M, Westermark B. Cell scattering and migration induced by autocrine transforming growth factor alpha in human glioma cells in vitro. Cancer Res. 1997;57(24):5598–604.

    CAS  PubMed  Google Scholar 

  11. Nazarenko I, Hede SM, He X, Hedren A, Thompson J, Lindstrom MS, et al. PDGF and PDGF receptors in glioma. Ups J Med Sci. 2012;117(2):99–112.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Linger RM, Keating AK, Earp HS, Graham DK. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets. 2010;14(10):1073–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, Nutt CL. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol. 2006;65(12):1181–8.

    Article  CAS  PubMed  Google Scholar 

  14. Balana C, Gil MJ, Perez P, Reynes G, Gallego O, Ribalta T, et al. Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a phase II study. Target Oncol. 2014;9(4):321–9.

    Article  PubMed  Google Scholar 

  15. Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol. 2010;12(8):855–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Thiessen B, Stewart C, Tsao M, Kamel-Reid S, Schaiquevich P, Mason W, et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol. 2010;65(2):353–61.

    Article  CAS  PubMed  Google Scholar 

  17. Uhm JH, Ballman KV, Wu W, Giannini C, Krauss JC, Buckner JC, et al. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int J Radiat Oncol Biol Phys. 2011;80(2):347–53.

    Article  CAS  PubMed  Google Scholar 

  18. Peereboom DM, Shepard DR, Ahluwalia MS, Brewer CJ, Agarwal N, Stevens GH, et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol. 2010;98(1):93–9.

    Article  CAS  PubMed  Google Scholar 

  19. Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, Kavan P, et al. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro Oncol. 2015;17(3):430–9.

    PubMed  PubMed Central  Google Scholar 

  20. Zustovich F, Landi L, Lombardi G, Porta C, Galli L, Fontana A, et al. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. Anticancer Res. 2013;33(8):3487–94.

    CAS  PubMed  Google Scholar 

  21. Endersby R, Baker SJ. PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene. 2008;27(41):5416–30.

    Article  CAS  PubMed  Google Scholar 

  22. Denysenko T, Gennero L, Juenemann C, Morra I, Masperi P, Ceroni V, et al. Heterogeneous phenotype of human glioblastoma: in vitro study. Cell Biochem Funct. 2014;32(2):164–76.

    Article  CAS  PubMed  Google Scholar 

  23. Roth P, Weller M. Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies. Neuro Oncol. 2014;16(Suppl 8):viii14–9.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Nakada M, Kita D, Watanabe T, Hayashi Y, Hamada J. Mechanism of chemoresistance against tyrosine kinase inhibitors in malignant glioma. Brain Tumor Pathol. 2014;31(3):198–207.

    Article  CAS  PubMed  Google Scholar 

  25. Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012;2(5):458–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Kouroukis TC, Baldassarre FG, Haynes AE, Imrie K, Reece DE, Cheung MC. Bortezomib in multiple myeloma: systematic review and clinical considerations. Curr Oncol. 2014;21(4):e573–603.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Chitra S, Nalini G, Rajasekhar G. The ubiquitin proteasome system and efficacy of proteasome inhibitors in diseases. Int J Rheum Dis. 2012;15(3):249–60.

    Article  CAS  PubMed  Google Scholar 

  28. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107(12):4907–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Vlachostergios PJ, Voutsadakis IA, Papandreou CN. The shaping of invasive glioma phenotype by the ubiquitin-proteasome system. Cell Commun Adhes. 2013;20(5):87–92.

    Article  CAS  PubMed  Google Scholar 

  30. Dalton WS. The proteasome. Semin Oncol. 2004;31(6 Suppl 16):3–9 (discussion 33).

    Article  CAS  PubMed  Google Scholar 

  31. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 2008;14(6):1649–57.

    Article  CAS  PubMed  Google Scholar 

  32. Grosicki S, Barchnicka A, Jurczyszyn A, Grosicka A. Bortezomib for the treatment of multiple myeloma. Expert Rev Hematol. 2014;7(2):173–85.

    Article  CAS  PubMed  Google Scholar 

  33. Styczynski J, Olszewska-Slonina D, Kolodziej B, Napieraj M, Wysocki M. Activity of bortezomib in glioblastoma. Anticancer Res. 2006;26(6B):4499–503.

    CAS  PubMed  Google Scholar 

  34. Friday BB, Anderson SK, Buckner J, Yu C, Giannini C, Geoffroy F, et al. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol. 2012;14(2):215–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Vlachostergios PJ, Papandreou CN. Efficacy of low dose temozolomide in combination with bortezomib in U87 glioma cells: a flow cytometric analysis. Arch Med Sci. 2015;11(2):307–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Odia Y, Kreisl TN, Aregawi D, Innis EK, Fine HA. A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas. J Neurooncol. 2015;125(1):191–5.

    Article  CAS  PubMed  Google Scholar 

  37. Fostier K, De Becker A, Schots R. Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma. Onco Targets Ther. 2012;5:237–44.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120(5):947–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110(9):3281–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Drappatz J, Norden AD, Wen PY. Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev Neurother. 2009;9(4):519–34.

    Article  PubMed  Google Scholar 

  41. Johnson DR, Chang SM. Recent medical management of glioblastoma. Adv Exp Med Biol. 2012;746:26–40.

    Article  CAS  PubMed  Google Scholar 

  42. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842–50.

    Article  CAS  PubMed  Google Scholar 

  43. van den Bent MJ, Hegi ME, Stupp R. Recent developments in the use of chemotherapy in brain tumours. Eur J Cancer. 2006;42(5):582–8.

    Article  PubMed  Google Scholar 

  44. Balyasnikova IV, Ferguson SD, Han Y, Liu F, Lesniak MS. Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts. Cancer Lett. 2011;310(2):148–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Foti C, Florean C, Pezzutto A, Roncaglia P, Tomasella A, Gustincich S, et al. Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system. Mol Cancer Ther. 2009;8(11):3140–50.

    Article  CAS  PubMed  Google Scholar 

  46. Kahana S, Finniss S, Cazacu S, Xiang C, Lee HK, Brodie S, et al. Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCepsilon-dependent downregulation of AKT and XIAP expressions. Cell Signal. 2011;23(8):1348–57.

    Article  CAS  PubMed  Google Scholar 

  47. Unterkircher T, Cristofanon S, Vellanki SH, Nonnenmacher L, Karpel-Massler G, Wirtz CR, et al. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin Cancer Res. 2011;17(12):4019–30.

    Article  CAS  PubMed  Google Scholar 

  48. Yin D, Zhou H, Kumagai T, Liu G, Ong JM, Black KL, et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene. 2005;24(3):344–54.

    Article  CAS  PubMed  Google Scholar 

  49. Zhang X, Li W, Wang C, Leng X, Lian S, Feng J, et al. Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells. Mol Cell Biochem. 2014;385(1–2):265–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67(13):6383–91.

    Article  CAS  PubMed  Google Scholar 

  51. Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci. 2009;16(6):748–54.

    Article  CAS  PubMed  Google Scholar 

  52. Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res. 2001;61(14):5349–54.

    CAS  PubMed  Google Scholar 

  53. Montgomery RB, Guzman J, O’Rourke DM, Stahl WL. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J Biol Chem. 2000;275(23):17358–63.

    Article  CAS  PubMed  Google Scholar 

  54. Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, Huang HJ. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 1996;56(21):5079–86.

    CAS  PubMed  Google Scholar 

  55. Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR, et al. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem. 1996;271(41):25639–45.

    Article  CAS  PubMed  Google Scholar 

  56. Kim K, Brush JM, Watson PA, Cacalano NA, Iwamoto KS, McBride WH. Epidermal growth factor receptor vIII expression in U87 glioblastoma cells alters their proteasome composition, function, and response to irradiation. Mol Cancer Res. 2008;6(3):426–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161–74.

    Article  CAS  PubMed  Google Scholar 

  58. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science. 1997;277(5323):225–8.

    Article  CAS  PubMed  Google Scholar 

  59. Musumeci G, Magro G, Cardile V, Coco M, Marzagalli R, Castrogiovanni P, et al. Characterization of matrix metalloproteinase-2 and -9, ADAM-10 and N-cadherin expression in human glioblastoma multiforme. Cell Tissue Res. 2015;362(1):45–60.

    Article  CAS  PubMed  Google Scholar 

  60. Williamson MJ, Blank JL, Bruzzese FJ, Cao Y, Daniels JS, Dick LR, et al. Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib. Mol Cancer Ther. 2006;5(12):3052–61.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Level 5, Clinical Sciences Building, Parkville, VIC, 3050, Australia

    Zammam Areeb, Stanley S. Stylli, Thomas M. B. Ware, Lucia Paradiso, Andrew P. Morokoff, Andrew H. Kaye & Rodney B. Luwor

  2. Department of Neurosurgery, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia

    Stanley S. Stylli, Andrew P. Morokoff & Andrew H. Kaye

  3. Regenerative Surgery Group, O’Brien Institute Tissue Engineering Centre, Fitzroy, VIC, 3065, Australia

    Nicole C. Harris, Lipi Shukla & Ramin Shayan

  4. Department of Plastic and Reconstructive Surgery, St Vincent’s Hospital, Fitzroy, VIC, 3065, Australia

    Nicole C. Harris, Lipi Shukla & Ramin Shayan

  5. Paediatric Neurosurgery, Department of Paediatric Surgery, Qilu Hospital, Shandong University, 107#, Wenhua Xi Road, Jinan, 250012, People’s Republic of China

    Bo Li

  6. Brain Science Research Institute of Shandong University, Jinan, 250012, People’s Republic of China

    Bo Li

Authors
  1. Zammam Areeb
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Stanley S. Stylli
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Thomas M. B. Ware
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Nicole C. Harris
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Lipi Shukla
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Ramin Shayan
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Lucia Paradiso
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. Bo Li
    View author publications

    You can also search for this author inPubMed Google Scholar

  9. Andrew P. Morokoff
    View author publications

    You can also search for this author inPubMed Google Scholar

  10. Andrew H. Kaye
    View author publications

    You can also search for this author inPubMed Google Scholar

  11. Rodney B. Luwor
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Rodney B. Luwor.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest or financial benefit from this publication.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Areeb, Z., Stylli, S.S., Ware, T.M.B. et al. Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib. Med Oncol 33, 53 (2016). https://doi.org/10.1007/s12032-016-0767-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-016-0767-3

Keywords